review · Cephalalgia
New evidence-based guidelines provide actionable recommendations for the pharmacological management of migraine across various healthcare settings. Developed through collaboration between the Italian Society for the Study of Headache and the International Headache Society, the recommendations combine findings from randomised controlled trials with expert opinion. The assessment followed the GRADE approach alongside standard Cochrane systematic review methodologies to evaluate evidence drawn from multiple databases. Beyond presenting guidance to standardise clinical practice and improve the consistency of patient care, the work identifies critical deficiencies in the existing scientific literature. In particular, it notes a lack of direct head-to-head comparisons between different migraine medications as well as an absence of adequate long-term outcome studies.
Migraine requires consistent and effective medical intervention. By establishing clear standards derived from systematic reviews and rigorous quality grading, these guidelines assist healthcare professionals in making reliable clinical decisions. Furthermore, identifying key knowledge deficits, such as the shortage of comparative drug trials and long-term evaluations, provides a clear roadmap for future clinical research priorities.
The work offers an immediate, ready-to-implement clinical decision-support framework for healthcare providers and clinical organisations aiming to standardise migraine prescribing practices. For pharmaceutical developers and clinical research organisations, the highlighted evidence gaps identify immediate opportunities to design head-to-head comparative drug trials and long-term outcome studies that can differentiate existing and emerging therapies.
AI-generated from the published abstract. Always read the original work before citing.
We here present evidence-based guidelines for the pharmacological treatment of migraine. These guidelines, created by the Italian Society for the Study of Headache and the International Headache Society, aim to offer clear, actionable recommendations to healthcare professionals. They incorporate evidence-based recommendations from randomized controlled trials and expert-based opinions. The guidelines follow the GRADE approach for assessing the quality of evidence. The guideline development involved a systematic review of literature across multiple databases, adherence to Cochrane review methods, and a structured framework for data extraction and interpretation. Although the guidelines provide a robust foundation for migraine treatment, they also highlight gaps in current research, such as the paucity of head-to-head drug comparisons and the need for long-term outcome studies. These guidelines serve as a resource to standardize migraine treatment and promote high-quality care across different healthcare settings.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1177/03331024251321500
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
